cerebral infarction
Conditions
Interventions
Agatroban combined with antiplatelet therapy group:While aspirin or clopidogrel alone was used for antiplatelet therapy, 60 mg of argatroban was dissolved in 120 mL of saline for 48 h on day 1-2 of th
Duplex antiplatelet therapy group:Administration of aspirin 100mg in combination with clopidogrel 75mg
Sponsors
Suzhou Municipal Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age between 18 and 80 years old; (2) Diagnosis of ischemic stroke confirmed by neuroimaging (CT or MRI), with the diagnostic criteria for ischemic stroke referring to the '2018 Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke'; (3) Onset time = 48 hours; (4) NIHSS score = 20 points; (5) Etiological classification as large artery atherosclerosis type (LAA) according to the definition in the CISS standard, based on medical history and imaging results from head MRI, MRA or CTA, carotid ultrasonography, electrocardiogram, and other examinations; (6) Signed informed consent obtained from the patient or their legal representative.
Exclusion criteria
Exclusion criteria: (1) Patients who have received thrombolysis or endovascular treatment; (2) Severe infections or serious diseases affecting the liver, kidneys, hematopoietic system, endocrine system, etc.; (3) Pre-morbid modified Rankin Scale (mRS) score of = 2; (4) Allergy to or inability to tolerate antiplatelet or anticoagulant medications such as aspirin, clopidogrel, and argatroban; (5) Ischemic stroke due to other causes, including small vessel disease, cardioembolic stroke, arterial dissection, vasculitis, among others, resulting in cerebral infarction; (6) High risk of bleeding, characterized by a prolonged activated partial thromboplastin time (APTT, normal range: 21.1-36.5 seconds) or low platelet count (<100×109/L); (7) Presence of cerebral hemorrhage, gastrointestinal bleeding, or having undergone major surgery within the last three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| good prognosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Early neurological deterioration;NIHSS score;Recurrent stroke;cardiovascular death;myocardial infarction;Complications of hemorrhage within 90 days;non-vascular death; | — |
Countries
china
Contacts
Public ContactGuanhui Wu
Suzhou Municipal Hospital
Outcome results
None listed